Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per Share
Newsfile·2025-09-10 20:37
Hemostemix Announces TSXV Approval of Debt Settlement at $0.20 per ShareSeptember 10, 2025 4:37 PM EDT | Source: Hemostemix Inc.Calgary, Alberta--(Newsfile Corp. - September 10, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Company"), the leading autologous (patient's own) stem cell therapy company offering VesCell™ (ACP-01) to individuals suffering from peripheral arterial disease, chronic limb threatening ischemia, angina, ischemic cardiomyopathy, non ischemic dilated card ...